Carmel Mission Inn, Carmel, CA 93923
January 24-25, 2014
The conference will consist of two half-day case-based sessions focusing onVenous Thromboembolism and Fungal Pulmonary Diseases. Friday’s session on Venous Thromboembolism will focus on the proper diagnostic algorithm and duration of treatment for PE, knowing when to use new oral anticoagulants, indications for thrombolysis and IVC filters, as well as prevention of venous thrombosis. Dr. Victor Tapson from Cedars-Sinai Medical Center will provide the keynote presentation on Friday. Saturday’s session on Fungal Lung Diseases will focus on the diagnosis and treatment of coccidioidomycosis as well as allergic and invasive aspergillosis.
A special hands on airways device clearance workshop and a Clinicians’ Luncheon will be held on Saturday. The Western Respiratory Club/CTS dinner with special guest speaker, Dr. Louise Aronson from UCSF will be held on Friday night. The CF Consortium will meet on Friday and Saturday.
Session One: Venous Thromboembolism
Friday Afternoon, January 24, 2014
Thromboembolism proper diagnostic algorithm for PE, proper duration of treatment, proper use of new oral anticoagulants, indications for thrombolysis and IVC filters and prevention of venous thrombosis will all be presented and discussed.
Western Respiratory Club / CTS Dinner
Topic: A History of the Present Illness: Telling the Stories of Doctors, Patients, and Medicine Today
Friday Night, January 24, 2014
Speaker: Louise Aronson, MD, UC San Francisco
Session Two: Fungal Pulmonary Disease
Saturday Afternoon, January 25, 2014
Fungal lung diseases particularly coccidioidomycosis are increasing in incidence and require an index of suspicion to diagnose. Treatment type and duration are also not widely understood. These topics and issues are the focus of this year’s conference.
• Recognize and diagnose cases of submassive pulmonary emboli (PE) in the outpatient and inpatient setting
• Properly diagnose heparin-induced thrombocytopenia (HIT) using clinical criteria and laboratory tests
• Choose the best diagnostic tests for coccidioidomycosis infection based on the severity of illness
• Understand the definition of fungal colonization and fungus-host interaction as it relates to allergic bronchopulmonary apergillosis (ABPA) in CF patients
• Identify both classic and emerging risk factors for invasive aspergillosis
• Know and understand the current evidence supporting the correct use of medications and devices for airway clearance in the pediatric population.
Continuing Medical Education Credits
This live activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Thoracic Society and the California Thoracic Society. The American Thoracic Society is accredited by the ACCME to provide continuing medical education for physicians.
The American Thoracic Society designates this educational activity for a maximum of 7.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CTS has been approved by the California Board of Registered Nursing, Provider Number 599 for 7.0 hours. This CTS course meets the requirements for CE for RCPs in California for 7.0 hours.
Airway Device Seminar & Demonstration | Saturday, 1:00pm – 3:00pm
The safety and efficacy of airway clearance in pediatric patients, whether inpatient, outpatient or critically ill remains a topic of great complexity and limited research. The vast majority of research on airway clearance in the pediatric population has been in the cystic fibrosis group. The standard of care for airway clearance has been considered conventional chest physiotherapy in the past, but numerous devices and medications have been developed to address the multiple aspects of the airway clearance process.
This seminar will offer a brief introduction to the postulated mechanisms of action in airway clearance, and evidence available to date confirming use and efficacy of medications and devices and currently used for airway clearance in various patient populations.